The Effect of Dydrogesterone on Sexual Function in Women With Endometriosis

Study Overview
=================
Brief Summary
-----------------
This study aimed to assess the effects of dydrogesterone on sexual function in women with endometriosis using Female Function Sexual Index (FSFI).

Detailed Description
-----------------
Sexual dysfunction is an important outcome for patients with endometriosis. In this study, we compare the fsfi (female sexual function index) questions and the scores before and after dydrogesterone treatment in patients with endometriosis. We aim to measure the effect of dydrogesterone in patients with endometriosis.

Official Title
-----------------
The Effect of Dydrogesterone on Sexual Function in Women With Endometriosis

Conditions
-----------------
Endometriosis, Sexual Dysfunction

Intervention / Treatment
-----------------
* Drug: Dydrogesterone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: no history of malignancies, normal findings at gynecological examinations and transvaginal ultrasonography normal uterine size, normal cervical smear results, patients not use any contraception methods in the last 6 months Exclusion Criteria: with a history of systemic and/or psychiatric diseases, gynecological pathologies (myoma uteri, endometriosis, uterine anomalies, existing genital infections) pelvic organ prolapse pelvic surgeries

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: women with endometriosis<br> | Drug: Dydrogesterone<br>* 79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Effect of Dydrogesterone on Sexual Function | In this study, we compare the fsfi(female sexual function index) questions and the scores before and after dihydrogestreone treatment in patients with endometriosis. We aim to measure the effect of dihydrogesterone in patients with endometriosis. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Effect of Dydrogesterone on Sexual Function in women with endometrioma | In this study, we compare the fsfi(female sexual function index) questions and the scores before and after dihydrogestreone treatment in patients with endometriosis. We aim to measure the effect of dihydrogesterone in patients with endometriosis.(with and without endometrioma) | 6 months |